Amounts due within one year to alliance partners.

No definition available.

Name:	bmy_AccountsPayableToAlliancePartners
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amounts due within one year from alliance or collaboration partners.

+ References

No definition available.

+ Details

Name:	bmy_AlliancePartnerReceivables
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

This element represents the amortization of an extension payment made to an alliance partner that is recognized as a reduction to net sales.

+ References

No definition available.

+ Details

Name:	bmy_AmortizationOfTheExtensionPayment
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of operating expense at or below which the collaboration partner will contribute a given percentage of reimbursements per the collaboration agreement.

+ References

No definition available.

+ Details

Name:	bmy_AmountOfOperatingExpenseAtOrBelowWhichCollaborationPartnerWillReimburseGivenPercentage
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of operating expense over which the collaboration partner will contribute a given percentage of reimbursements per the collaboration agreement.

+ References

No definition available.

+ Details

Name:	bmy_AmountOfOperatingExpenseOverWhichCollaborationPartnerWillReimburseGivenPercentage
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of total deferred income attributable to disposal group, current and noncurrent.

+ References

No definition available.

+ Details

Name:	bmy_DisposalGroupIncludingDiscontinuedOperationTotalDeferredIncome
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The pre-tax portion of income/(loss) attributable to the noncontrolling interest (if any) deducted in order to derive the portion attributable to the parent.

+ References

No definition available.

+ Details

Name:	bmy_NetIncomeLossAttributableToNoncontrollingInterestPretax
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of an oncology product fee paid to an alliance partner during the period, which is recognized in cost of products sold.

+ References

No definition available.

+ Details

Name:	bmy_OncologyAllianceFee
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

This element represents payments to or (from) alliance partners during the period, which are included in advertising and product promotion expense.

+ References

No definition available.

+ Details

Name:	bmy_PaymentsToFromAlliancePartnerRecognizedInAdvertisingAndProductPromotion
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

This element represents payments to or (from) alliance partners during the period, which are included in research and development.

+ References

No definition available.

+ Details

Name:	bmy_PaymentsToFromAlliancePartnerRecognizedInResearchAndDevelopment
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

This element represents payments to or (from) alliance partners during the period, which are included in costs of products sold.

+ References

No definition available.

+ Details

Name:	bmy_PaymentsToFromAlliancePartnersRecognizedInCostofProductsSold
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

This element represents payments to or (from) alliance partners during the period, which are included in marketing, selling and administrative expenses.

+ References

No definition available.

+ Details

Name:	bmy_PaymentsToFromAlliancePartnersRecognizedInMarketingSellingAndAdministrative
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

This element represents payments to or (from) alliance partners during the period, which are included in other (income)/expense.

+ References

No definition available.

+ Details

Name:	bmy_PaymentsToFromAlliancePartnersRecognizedInOtherIncomeExpense
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

This element represents the payment made to extend the term of the commercialization and manufacturing agreement, which is included in other assets and amortized as a reduction of net sales through the extension period.

+ References

No definition available.

+ Details

Name:	bmy_PaymentToExtendTermOfCommercializationAgreement
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

This element represents payments to or (from) alliance partners for the costs of product supply during the period, which are included in cost of products sold.

+ References

No definition available.

+ Details

Name:	bmy_PaymentToFromCostofProductSupply
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The percentage of annual net sales of certain products payable as a collaboration fee to third parties in alliances and collaborations.

+ References

No definition available.

+ Details

Name:	bmy_PercentageOfNetSalesPayableToCollaborationPartner
Namespace Prefix:	bmy_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The percentage of sales to be recognized pursuant to the collaboration agreement.

+ References

No definition available.

+ Details

Name:	bmy_PercentageOfNetSalesRecognizedFromCollaboration
Namespace Prefix:	bmy_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The percentage of operating expenses to be reimbursed by the collaboration partner pursuant to the collaboration agreement.

+ References

No definition available.

+ Details

Name:	bmy_PercentageOfOperatingExpenseReimbursementsFromCollaboration
Namespace Prefix:	bmy_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

This element represents the percentage of sales recognized by the Company when it is the principal in the customer sale.

+ References

No definition available.

+ Details

Name:	bmy_PercentageOfSalesRecognized
Namespace Prefix:	bmy_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The maximum amount of sales within a range for which a given percentage will be paid to the collaboration partner as a collaboration fee per the collaboration agreement.

+ References

No definition available.

+ Details

Name:	bmy_RangeOfSalesAtWhichGivenPercentageWillBePaidToCollaborationPartnerMaximum
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The minimum amount of sales within a range for which a given percentage will be paid to the collaboration partner as a collaboration fee per the collaboration agreement.

+ References

No definition available.

+ Details

Name:	bmy_RangeOfSalesAtWhichGivenPercentageWillBePaidToCollaborationPartnerMinimum
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name:	us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Total carrying amount of consideration received or receivable as of the balance sheet date representing potential earnings that were not as yet recognized as revenue or other forms of income in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenueAndCredits
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name:	us-gaap_OtherAssetsNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_OtherNonoperatingIncomeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a),(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_OtherSalesRevenueNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_SalesRevenueGoodsNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_SalesRevenueNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	bmy_AlliancesAndCollaborationCompaniesAxis=bmy_AlliancePartnersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	bmy_AlliancesAndCollaborationCompaniesAxis=bmy_OtsukaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=bmy_AbilifyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

ALLIANCES (Otsuka) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 30, 2009
Alliances Statement [Line Items]
Percentage of third-party product sales recognized when BMS is the principal in the end customer sale	100.00%bmy_PercentageOfSalesRecognized								100.00%bmy_PercentageOfSalesRecognized
Net product sales									$ 11,660us-gaap_SalesRevenueGoodsNet	$ 12,304us-gaap_SalesRevenueGoodsNet	$ 13,654us-gaap_SalesRevenueGoodsNet
Alliance and other revenues									4,219us-gaap_OtherSalesRevenueNet	4,081us-gaap_OtherSalesRevenueNet	3,967us-gaap_OtherSalesRevenueNet
Total Revenues	4,258us-gaap_SalesRevenueNet	3,921us-gaap_SalesRevenueNet	3,889us-gaap_SalesRevenueNet	3,811us-gaap_SalesRevenueNet	4,441us-gaap_SalesRevenueNet	4,065us-gaap_SalesRevenueNet	4,048us-gaap_SalesRevenueNet	3,831us-gaap_SalesRevenueNet	15,879us-gaap_SalesRevenueNet	16,385us-gaap_SalesRevenueNet	17,621us-gaap_SalesRevenueNet
Receivables - from alliance partners	888bmy_AlliancePartnerReceivables				1,122bmy_AlliancePartnerReceivables				888bmy_AlliancePartnerReceivables	1,122bmy_AlliancePartnerReceivables
Accounts payable - to alliance partners	1,479bmy_AccountsPayableToAlliancePartners				1,396bmy_AccountsPayableToAlliancePartners				1,479bmy_AccountsPayableToAlliancePartners	1,396bmy_AccountsPayableToAlliancePartners
Deferred income	1,937us-gaap_DeferredRevenueAndCredits				1,525us-gaap_DeferredRevenueAndCredits				1,937us-gaap_DeferredRevenueAndCredits	1,525us-gaap_DeferredRevenueAndCredits
Deferred income from alliances included in liabilities related to assets held-for-sale					3,671					3,671
Cost of products sold - Amortization of intangible assets									286us-gaap_AmortizationOfIntangibleAssets	858us-gaap_AmortizationOfIntangibleAssets	607us-gaap_AmortizationOfIntangibleAssets
Other assets - extension payment	621us-gaap_OtherAssetsNoncurrent				1,428us-gaap_OtherAssetsNoncurrent				621us-gaap_OtherAssetsNoncurrent	1,428us-gaap_OtherAssetsNoncurrent
Other Nonoperating Income (Expense)									(210)us-gaap_OtherNonoperatingIncomeExpense	(205)us-gaap_OtherNonoperatingIncomeExpense	80us-gaap_OtherNonoperatingIncomeExpense
Abilify [Member]
Alliances Statement [Line Items]
Alliance and other revenues									1,778	1,840	2,340
Total Revenues									2,020	2,289	2,827
Alliance Partners [Member]
Alliances Statement [Line Items]
Net product sales									3,531	4,417	6,124
Alliance and other revenues									3,828	3,804	3,748
Total Revenues									7,359	8,221	9,872
Payments to/(from) alliance partner- Cost of products sold									1,394	1,356	1,706
Payments to/(from) alliance partner - Marketing, selling and administrative									44	(125)	(80)
Payments to/(from) alliance partner - Advertising and product promotion									90	(58)	(97)
Payments to/(from) alliance partner - Research and development									(70)	(140)	4
Payments to/(from) alliance partners - Other (income)/expense									(1,076)	(313)	(489)
Noncontrolling interest, pre-tax									38	36	844
Deferred income	1,493				5,089				1,493	5,089
Otsuka [Member]
Alliances Statement [Line Items]
Net product sales									1,493	1,543	1,386
Alliance and other revenues									1,778	1,840	2,340
Total Revenues									3,271	3,383	3,726
Payments to/(from) alliance partner- Cost of products sold									3	3	2
Payments to/(from) alliance partner - Marketing, selling and administrative									61	34	7
Payments to/(from) alliance partner - Advertising and product promotion									32	(42)	(49)
Payments to/(from) alliance partner - Research and development									3	(5)	(7)
Percentage of net sales recognized from alliance	33.00%				34.00%				33.00%	34.00%	51.50%
Cost of products sold - Cost of product supply									67	135	153
Amortization of the extension payment									66	66	66
Other Nonoperating Income (Expense)									(9)
Otsuka [Member] \| United States [Member] \| Abilify [Member]
Alliances Statement [Line Items]
Percentage of net sales payable to alliance partner	1.50%								1.50%
Percentage of operating expense reimbursements from alliance											30.00%
Cost of products sold - Royalties									90	86	78
Otsuka [Member] \| United States [Member] \| Abilify [Member] \| Annual net sales up to 2 Point 7 billion [Member]
Alliances Statement [Line Items]
Percentage of net sales recognized from alliance	50.00%								50.00%
Range of sales at which a given percentage will be paid to alliance partner - maximum									2,700
Otsuka [Member] \| United States [Member] \| Abilify [Member] \| Annual net sales between 2 Point 7 billion and 3 Point 2 billion [Member]
Alliances Statement [Line Items]
Percentage of net sales recognized from alliance	20.00%								20.00%
Range of sales at which a given percentage will be paid to alliance partner - minimum									2,700
Range of sales at which a given percentage will be paid to alliance partner - maximum									3,200
Otsuka [Member] \| United States [Member] \| Abilify [Member] \| Annual net sales between 3 Point 2 billion and 3 Point 7 billion [Member]
Alliances Statement [Line Items]
Percentage of net sales recognized from alliance	7.00%								7.00%
Range of sales at which a given percentage will be paid to alliance partner - minimum									3,200
Range of sales at which a given percentage will be paid to alliance partner - maximum									3,700
Otsuka [Member] \| United States [Member] \| Abilify [Member] \| Annual net sales between 3 Point 7 billion and 4 Point 0 billion [Member]
Alliances Statement [Line Items]
Percentage of net sales recognized from alliance	2.00%								2.00%
Range of sales at which a given percentage will be paid to alliance partner - minimum									3,700
Range of sales at which a given percentage will be paid to alliance partner - maximum									4,000
Otsuka [Member] \| United States [Member] \| Abilify [Member] \| Annual net sales between 4 Point 0 billion and 4 Point 2 billion [Member]
Alliances Statement [Line Items]
Percentage of net sales recognized from alliance	1.00%								1.00%
Range of sales at which a given percentage will be paid to alliance partner - minimum									4,000
Range of sales at which a given percentage will be paid to alliance partner - maximum									4,200
Otsuka [Member] \| United States [Member] \| Abilify [Member] \| Annual net sales over 4 Point 2 billion [Member]
Alliances Statement [Line Items]
Percentage of net sales recognized from alliance	20.00%								20.00%
Range of sales at which a given percentage will be paid to alliance partner - minimum									4,200
Otsuka [Member] \| United States [Member] \| Abilify [Member] \| Extension payment [Member]
Alliances Statement [Line Items]
Payment to extend term of commercialization agreement												400
Other assets - extension payment	21				87				21	87
Otsuka [Member] \| United States [Member] \| Abilify [Member] \| Upfront, milestone and other licensing payments [Member]
Alliances Statement [Line Items]
Cost of products sold - Amortization of intangible assets											5
Otsuka [Member] \| European Union [Member] \| Abilify [Member]
Alliances Statement [Line Items]
Percentage of net sales recognized from alliance	65.00%								65.00%
Otsuka [Member] \| Oncology Territory [Member] \| Sprycel and Ixempra [Member]
Alliances Statement [Line Items]
Cost of products sold - Oncology fee									297	295	138
Otsuka [Member] \| Oncology Territory [Member] \| Sprycel and Ixempra [Member] \| Operating expense up to $175 million [Member]
Alliances Statement [Line Items]
Percentage of operating expense reimbursements from alliance	20.00%								20.00%
Amount of operating expense at or below which alliance partner will reimburse given percentage	175								175
Otsuka [Member] \| Oncology Territory [Member] \| Sprycel and Ixempra [Member] \| Operating expenses over $175 million [Member]
Alliances Statement [Line Items]
Percentage of operating expense reimbursements from alliance	1.00%								1.00%
Amount of operating expense over which alliance partner will reimburse given percentage	175								175
Otsuka [Member] \| Oncology Territory [Member] \| Sprycel and Ixempra [Member] \| Annual net sales up to $400 million [Member]
Alliances Statement [Line Items]
Percentage of net sales payable to alliance partner	65.00%								65.00%		30.00%
Range of sales at which a given percentage will be paid to alliance partner - maximum									400
Otsuka [Member] \| Oncology Territory [Member] \| Sprycel and Ixempra [Member] \| Annual net sales between $400 and $600 million [Member]
Alliances Statement [Line Items]
Percentage of net sales payable to alliance partner	12.00%								12.00%		5.00%
Range of sales at which a given percentage will be paid to alliance partner - minimum									400
Range of sales at which a given percentage will be paid to alliance partner - maximum									600
Otsuka [Member] \| Oncology Territory [Member] \| Sprycel and Ixempra [Member] \| Annual net sales between $600 and $800 million [Member]
Alliances Statement [Line Items]
Percentage of net sales payable to alliance partner	3.00%								3.00%		3.00%
Range of sales at which a given percentage will be paid to alliance partner - minimum									600
Range of sales at which a given percentage will be paid to alliance partner - maximum									800
Otsuka [Member] \| Oncology Territory [Member] \| Sprycel and Ixempra [Member] \| Annual net sales between $800 million and $1 billion [Member]
Alliances Statement [Line Items]
Percentage of net sales payable to alliance partner	2.00%								2.00%		2.00%
Range of sales at which a given percentage will be paid to alliance partner - minimum									800
Range of sales at which a given percentage will be paid to alliance partner - maximum									1,000
Otsuka [Member] \| Oncology Territory [Member] \| Sprycel and Ixempra [Member] \| Annual net sales over $1 billion [Member]
Alliances Statement [Line Items]
Percentage of net sales payable to alliance partner	1.00%								1.00%		1.00%
Range of sales at which a given percentage will be paid to alliance partner - minimum									$ 1,000